Handbook of Neuroemergency Clinical Trials - 2nd Edition - ISBN: 9780128040645, 9780128041017

Handbook of Neuroemergency Clinical Trials

2nd Edition

Editors: Brett Skolnick Wayne Alves
eBook ISBN: 9780128041017
Hardcover ISBN: 9780128040645
Imprint: Academic Press
Published Date: 14th November 2017
Page Count: 400
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Handbook of Neuroemergency Clinical Trials, Second Edition, focuses on the practice of clinical trials in acute neuroscience populations, or what have been called neuroemergencies. Neuroemergencies are complex, life-threatening diseases and disorders, often with devastating consequences, including death or disability. The overall costs are staggering in terms of annual incidence and costs associated with treatment and survival, yet despite their significance as public health issues, there are few drugs and devices available for definitive treatment. The book focuses on novel therapies and the unique challenges their intended targets pose for the design and analysis of clinical trials.

This volume provides neurologists, neuroscientists, and drug developers with a more complete understanding of the scientific and medical issues of relevance in designing and initiating clinical development plans for novel drugs intended for acute neuroscience populations. The editors provide the best understanding of the pitfalls associated with acute CNS drug development and the best information on how to approach and solve issues that have plagued drug development.

Key Features

  • Presents a comprehensive overview on clinical trials and drug development challenges in acute neuroscience populations
  • Provides neurologists, neuroscientists and drug developers with a complete understanding of scientific and medical issues related to designing clinical trials
  • Edited by leaders in the field who have designed and managed over 50 neuroemergency clinical trials


Researchers and clinical practitioners in neuroscience, neurology, pharmacology and biostatistics

Table of Contents

1. Acute Ischemic Stroke
2. Subarachnoid Hemorrhage
3. Clinical Trials in Spontaneous Intracerebral Hemorrhage
4. Imaging Biomarkers in Stroke Trials

5. Traumatic Brain Injury
6. Improving approaches to evaluate efficacy and safety of drugs for traumatic brain injury
7. Brain Imaging in Traumatic Brain Injury
8. The Use of Blood-Based Biomarkers to Improve the Design of Clinical Trials of Traumatic Brain Injury
9. Biostatistical Issues in TBI Clinical Trials

10. Acute Seizures and Status Epilepticus
11. Post-traumatic Seizures

12. Neuroemergencies in Critical Care Patients
13. Neuro-Emergency Clinical Trials: Migraine
14. Acute Visual Deficits

15. Implications for new trials in acute ischemic stroke in the new era of endovascular therapy

16. The Role of a Project Medical Officer in Acute Neuroemergency Clinical Studies
17. Regulatory Considerations
18. Military Perspectives on Brain Injuries: Implications for Clinical Trials


No. of pages:
© Academic Press 2018
Academic Press
eBook ISBN:
Hardcover ISBN:

About the Editor

Brett Skolnick

Dr. Skolnick is a Clinical Associate Professor of Neurosurgery at North Shore-LIJ School of Medicine in Manhasset, New York. He has a broad based experience with development responsibilities in neurology that includes Intracerebral hemorrhage, traumatic brain injury and stroke as well as more recently in the area of inflammation having worked on the development of multiple monoclonal antibodies in Psoriasis, Rheumatoid Arthritis, Crohn’s disease and Ulcerative Colitis. Dr. Skolnick has previously worked as a clinical development consultant to pharmaceutical companies with a focus on early novel drug development.

Affiliations and Expertise

Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ, USA

Wayne Alves

Dr. Alves is Vice President of Clinical Operations at Evoke Pharmaceuticals, Inc. in Solana, California. He has held academic positions conducting basic clinical research in neuroemergency populations, and has served as consultant to numerous companies seeking to develop novel drugs.

Affiliations and Expertise

Valeant Pharmaceuticals Inc., Costa Mesa, CA, USA

Ratings and Reviews